Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Aclarion Inc (ACONW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: ACONW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -67.27% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.21 | 52 Weeks Range 0.01 - 0.10 | Updated Date 06/28/2025 |
52 Weeks Range 0.01 - 0.10 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7855.96% |
Management Effectiveness
Return on Assets (TTM) -35.44% | Return on Equity (TTM) -72.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 582330 |
Shares Outstanding - | Shares Floating 582330 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Aclarion Inc
Company Overview
History and Background
Aclarion, Inc. is a spine technology company transforming the diagnosis of lower back pain with its proprietary Magnetic Resonance Spectroscopy (MRS) technology and machine learning algorithms.
Core Business Areas
- Nociscan: A noninvasive tool aiding in the diagnosis of chronic low back pain (cLBP) by identifying painful spinal discs using advanced MR spectroscopy.
Leadership and Structure
Details on leadership and structure are not widely available publicly, indicative of a smaller, more specialized company. Investors should research this further.
Top Products and Market Share
Key Offerings
- Nociscan: Aclarion's core product, Nociscan, aims to improve diagnostic accuracy for cLBP. Market share is currently developing; specific data unavailable. Competitors include traditional diagnostic methods like MR imaging and discography, along with alternative therapies.
Market Dynamics
Industry Overview
The market focuses on diagnosing and treating chronic low back pain, a significant healthcare burden. Innovation is driven by the need for more accurate and non-invasive diagnostic tools.
Positioning
Aclarion positions itself as a leader in advanced diagnostic technology for cLBP, offering a non-invasive alternative to traditional methods. Aclarion is differentiated based on its MRS technology.
Total Addressable Market (TAM)
The total addressable market for cLBP diagnostics and treatment is substantial, estimated at billions of dollars annually. Aclarion is positioned to capture a segment of this market by offering improved diagnostic accuracy.
Upturn SWOT Analysis
Strengths
- Proprietary MRS technology
- Potential for improved diagnostic accuracy
- Non-invasive approach
Weaknesses
- Limited market presence
- Need for clinical validation
- Financial constraints
Opportunities
- Partnerships with hospitals and clinics
- Expansion of product applications
- Increased awareness of cLBP
Threats
- Competition from established players
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- SIEN
- SEDG
- NUVA
- Globus Medical (GMED)
Competitive Landscape
Aclarion faces competition from established medical device companies and alternative diagnostic methods. Its MRS technology provides a potential advantage, but market acceptance and reimbursement are key challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires deeper investor due diligence.
Future Projections: Future growth projections are based on adoption of Nociscan and further product development; analyst estimates unavailable.
Recent Initiatives: Recent initiatives include clinical trials and partnerships to validate and commercialize Nociscan.
Summary
Aclarion is a high-risk, high-reward investment. Its proprietary technology holds promise in improving cLBP diagnosis, but it faces challenges in market adoption, regulatory hurdles, and competition. Financial performance is largely dependent on successful commercialization. Investors should conduct thorough due diligence before investing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
Data is based on publicly available information and may not be comprehensive. Investment decisions should be based on independent research and professional advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aclarion Inc
Exchange NASDAQ | Headquaters Broomfield, CO, United States | ||
IPO Launch date 2022-04-22 | CEO, President & Director Mr. Brent Ness | ||
Sector Healthcare | Industry Health Information Services | Full time employees 5 | Website https://www.aclarion.com |
Full time employees 5 | Website https://www.aclarion.com | ||
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and data transfer products, including AMBRA Healthcare, an imaging data transfer platform and NOCIWEB, a custom developed web-interface. In addition, it offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.